Evidence map›Paper›PMID 38272669›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2024

Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine.

Candace B Johnson, Donna Walther, Matthew J Baggott, Lisa E Baker, Michael H Baumann

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Candace B JohnsonDepartment of Psychology, Western Michigan University, Kalamazoo, Michigan (C.B.J., L.E.B.); Designer Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland (D.W., M.H.B.); and Tactogen Inc., Palo Alto, California (M.J.B.).
Donna WaltherDepartment of Psychology, Western Michigan University, Kalamazoo, Michigan (C.B.J., L.E.B.); Designer Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland (D.W., M.H.B.); and Tactogen Inc., Palo Alto, California (M.J.B.).
Matthew J BaggottDepartment of Psychology, Western Michigan University, Kalamazoo, Michigan (C.B.J., L.E.B.); Designer Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland (D.W., M.H.B.); and Tactogen Inc., Palo Alto, California (M.J.B.).
Lisa E BakerDepartment of Psychology, Western Michigan University, Kalamazoo, Michigan (C.B.J., L.E.B.); Designer Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland (D.W., M.H.B.); and Tactogen Inc., Palo Alto, California (M.J.B.).
Michael H BaumannDepartment of Psychology, Western Michigan University, Kalamazoo, Michigan (C.B.J., L.E.B.); Designer Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland (D.W., M.H.B.); and Tactogen Inc., Palo Alto, California (M.J.B.) mbaumann@mail.nih.gov matt@tactogen.com.
National Institute on Drug Abuse · USWestern Michigan University · US

Funding

Preclinical medication development for stimulant use disorderZIADA000522 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI BAUMANN, MICHAEL · 2009 to 2025
$8.9M
Development of Dual Dopamine/Serotonin Releasing AgentsZ01DA000522 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI ROTHMAN, RICHARD · 2008 to 2008
$598k
Intramural NIH HHS Z01 DA000522
6 · The paper itself

Abstract

3,4-Methylenedioxymethamphetamine (MDMA) has shown efficacy as a medication adjunct for treating post-traumatic stress disorder (PTSD). However, MDMA is also used in nonmedical contexts that pose risk for cardiovascular and neurologic complications. It is well established that MDMA exerts its effects by stimulating transporter-mediated release of the monoamines 5-hydroxytryptamine (5-HT), norepinephrine, and dopamine. Current research efforts are aimed at developing MDMA-like monoamine releasers with better efficacy and safety profiles. To this end, we investigated neurochemical and behavioral effects of novel analogs of the designer drug 5-(2-methylaminopropyl)benzofuran (5-MAPB). We used in vitro transporter assays in rat brain synaptosomes to examine transmitter uptake inhibition and releasing properties for enantiomers of 5-(2-methylaminobutyl)benzofuran (5-MABB) and 6-(2-methylaminobutyl)benzofuran (6-MABB) compared with MDMA. We then tested these same compounds in male Sprague-Dawley rats trained to discriminate MDMA (1.5 mg/kg) from saline. In vitro results revealed that

Indexed as

BenzofuransN-Methyl-3,4-methylenedioxyamphetamineRats, Sprague-DawleyAnimalsBiogenic MonoaminesDiscrimination, PsychologicalDopamineDopamine Plasma Membrane Transport ProteinsMaleNorepinephrineNorepinephrine Plasma Membrane Transport ProteinsRatsSerotoninSerotonin Plasma Membrane Transport ProteinsSynaptosomesBenzofuransBiogenic MonoaminesDopamineDopamine Plasma Membrane Transport ProteinsN-Methyl-3,4-methylenedioxyamphetamineNorepinephrineNorepinephrine Plasma Membrane Transport ProteinsSerotoninSerotonin Plasma Membrane Transport Proteins

Identifiers

PMID38272669
PMCPMC11413916
OpenAlexW4391213243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.